01 January 2000
High-dose anthracyclines in the treatment of advanced primitive neuroectodermal tumors in adults - a single institution experience.
Davorin Radosavljević, Svietislav Jelić, Zoran Tomasević, Suzana Matković, Ljiljana Stamatović, Zorica Nikolić-Tomasević, Ivan PopovMed Sci Monit 2000; 6(3): CR512-518 :: ID: 421316
Abstract
Primitive neuroectodermal tumors (PNET) are rare malignancies of presumedneural crest origin, most often presenting as bone or soft tissue masses in the trunk or axial skeleton,in children and young adults. Treatment of advanced PNET in adults is not clearly defined in the literature.Data concerning dose-intensive chemotherapy regimens for poor-risk patients with those tumors are sparse,due to rarity of PNET in adults, their diverse presentation, the variable treatment procedures appliedand the absence of direct comparisons. On the other hand, the role of anthracyclines in the treatmentof advanced soft tissue sarcomas is well known and substantial. Six advanced PNET patients were treatedat the Institute for Oncology and Radiology of Serbia, during last five years, with high-doses of doxorubicinor epidoxorubicin combined with cisplatin. The paper reviews each of our patients, discussing how doeschemotherapy influence the outcome in these patients, in context of the feasibility of high-doses ofanthracyclines in advanced settings. High dose anthracyclines (epidoxorubicin 150 mg/m2) in combinationwith cisplatin 120 mg/m2 induced a complete response lasting for 63+ months in a patient with desmoplasticmedulloblastoma of the cerebellum metastatic to bones and bone marrow. The same treatment but with theepidoxorubicin dose of 180 mg/m2 induced a complete response in a patient with olfactory neuroblastoma.Administration of high dose Doxorubicin (75 mg/m2) seems feasible in association with irradiation treatmentin patients with extraosseal Ewing sarcoma/PNET but the place of high dose chemotherapy within this settingremains to be determined.
Keywords: Antibiotics, Antineoplastic, Cerebellar Neoplasms, Disease-Free Survival, Epirubicin, Medulloblastoma, Neuroblastoma, Neuroectodermal Tumors, Primitive
774 3
Editorial
01 November 2023 : Editorial
Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is DeclaredDOI: 10.12659/MSM.942960
Med Sci Monit 2023; 29:e942960
In Press
30 Nov 2023 : Review article
Decoding the Neurological Sequelae of General Anesthesia: A ReviewMed Sci Monit In Press; DOI:
30 Nov 2023 : Clinical Research
Enhanced Pain Relief and Muscle Growth in Individuals with Low Back Instability: The Impact of Blood Flow R...Med Sci Monit In Press; DOI:
29 Nov 2023 : Clinical Research
Comparative Analysis of Intramedullary Nail versus Plate Fixation for Fibula Fracture in Supination Externa...Med Sci Monit In Press; DOI:
29 Nov 2023 : Clinical Research
Impact of COVID-19 on Academic Burnout among Medical College Students in China: Findings from a Web-Based S...Med Sci Monit In Press; DOI:
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292